Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Vernon M Holers

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/724-7605

    Collapse Research 
    Collapse research activities and funding
    P30AR079369     (HOLERS, VERNON MICHAEL)Sep 10, 2021 - Aug 31, 2026
    NIH
    Center for Mucosal Immunobiology and Rheumatic Disease Pathogenesis
    Role: Principal Investigator

    R56AR051749     (HOLERS, VERNON MICHAEL)Sep 23, 2020 - Aug 31, 2021
    NIH
    Complement in the Pathogenesis of Autoimmune Arthritis
    Role: Principal Investigator

    R01DK125823     (THURMAN, JOSHUA M)Jul 1, 2020 - May 31, 2024
    NIH
    Novel Therapeutic Approaches for Lupus Nephritis
    Role: Co-Principal Investigator

    UH2AR067681     (HOLERS, VERNON MICHAEL)Sep 24, 2014 - May 31, 2021
    NIH
    Evolving Adaptive and Effector Mechanisms from Pre-RA Through Established Disease
    Role: Principal Investigator

    UM2AR067678     (UTZ, PAUL JOSEPH)Sep 24, 2014 - May 31, 2021
    NIH
    AMP RA/SLE Leadership Center
    Role: Co-Principal Investigator

    UM1AI110503     (HOLERS, VERNON MICHAEL)May 1, 2014 - Apr 30, 2019
    NIH
    Colorado Autoimmunity Center of Excellence
    Role: Principal Investigator

    R21AI105717     (HOLERS, VERNON MICHAEL)Feb 1, 2013 - Jan 31, 2015
    NIH
    Disconnecting CR2/CD21 from Its C3d Ligand to Ameliorate Lupus
    Role: Principal Investigator

    U01AI101981     (HOLERS, VERNON MICHAEL)Jul 5, 2012 - Jun 30, 2022
    NIH
    Prevention Center U01: Early Targets for Antigen-Specific Tolerance Induction in Preclinical Rheumatoid Arthritis
    Role: Principal Investigator

    R01AR051394     (NORRIS, JILL M)Jul 18, 2005 - Jun 30, 2012
    NIH
    RA-Related Autoantibodies in Healthy FDR of RA Patients
    Role: Co-Principal Investigator

    R01AR051749     (HOLERS, VERNON MICHAEL)Sep 10, 2004 - Dec 31, 2025
    NIH
    Complement in the Pathogenesis of Autoimmune Arthritis
    Role: Principal Investigator

    R21AI061479     (HOLERS, VERNON MICHAEL)Jul 15, 2004 - Jun 30, 2006
    NIH
    Evolution of Autoimmunity in Rheumatoid Arthritis
    Role: Principal Investigator

    R13AR048234     (CRONSTEIN, BRUCE NEIL)Jul 1, 2002 - Jun 30, 2015
    NIH
    ACR Basic Research Conference
    Role: Co-Principal Investigator

    U19AI046374     (HOLERS, VERNON MICHAEL)Sep 28, 1999 - Aug 31, 2003
    NIH
    Denver Autoimmunity Center of Excellence
    Role: Principal Investigator

    R01AI031105     (HOLERS, VERNON MICHAEL)Jun 1, 1993 - Jun 30, 2003
    NIH
    Mouse Membrane RCA Proteins in the Immune Response
    Role: Principal Investigator

    R01CA053615     (HOLERS, VERNON MICHAEL)Jul 1, 1991 - Jul 31, 1999
    NIH
    C3d/EBV Receptor Ligand Binding Sites
    Role: Principal Investigator

    T32AR007534     (HOLERS, VERNON MICHAEL)Aug 1, 1986 - Jun 30, 2022
    NIH
    Research Training in Rheumatology
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Bergstedt DT, Tarter WJ, Peterson RA, Feser ML, Parish MC, Striebich CC, Demoruelle MK, Moss L, Bemis EA, Norris JM, Holers VM, Edison JD, Thiele GM, Mikuls TR, Deane KD. Antibodies to Citrullinated Protein Antigens, Rheumatoid Factor Isotypes and the Shared Epitope and the Near-Term Development of Clinically-Apparent Rheumatoid Arthritis. Front Immunol. 2022; 13:916277. PMID: 35812446.
      View in: PubMed
    2. Fahnoe KC, Liu F, Morgan JG, Ryan ST, Storek M, Stark EG, Taylor FR, Holers VM, Thurman JM, Wawersik S, Kalled SL, Violette SM. Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased Tissue. Front Immunol. 2022; 13:869725. PMID: 35784298.
      View in: PubMed
    3. Wong CJ, Wang L, Holers VM, Frazer-Abel A, van der Maarel SM, Tawil R, Statland JM, Tapscott SJ. Elevated plasma complement components in facioscapulohumeral dystrophy. Hum Mol Genet. 2022 06 04; 31(11):1821-1829. PMID: 34919696.
      View in: PubMed
    4. Vanderlinden LA, Bemis EA, Seifert J, Guthridge JM, Young KA, Demoruelle MK, Feser M, DeJager W, Macwana S, Mikuls TR, O'Dell JR, Weisman MH, Buckner J, Keating RM, Gaffney PM, Kelly JA, Langefeld CD, Deane KD, James JA, Holers VM, Norris JM. Relationship Between a Vitamin D Genetic Risk Score and Autoantibodies Among First-Degree Relatives of Probands With Rheumatoid Arthritis and Systemic Lupus Erythematosus. Front Immunol. 2022; 13:881332. PMID: 35720397.
      View in: PubMed
    5. Banda NK, Deane KD, Bemis EA, Strickland C, Seifert J, Jordan K, Goldman K, Morgan BP, Moreland LW, Lewis MJ, Pitzalis C, Holers VM. Analysis of Complement Gene Expression, Clinical Associations, and Biodistribution of Complement Proteins in the Synovium of Early Rheumatoid Arthritis Patients Reveals Unique Pathophysiologic Features. J Immunol. 2022 06 01; 208(11):2482-2496. PMID: 35500934.
      View in: PubMed
    6. Marin AI, Poppelaars F, Wagner BD, Palestine AG, Patnaik JL, Holers VM, Frazer-Abel AA, Mathias MT, Manoharan N, Fonteh CN, Mandava N, Lynch AM. Sex and Age-Related Differences in Complement Factors Among Patients With Intermediate Age-Related Macular Degeneration. Transl Vis Sci Technol. 2022 05 02; 11(5):22. PMID: 35594041.
      View in: PubMed
    7. Fechtner S, Berens H, Bemis E, Johnson RL, Guthridge CJ, Carlson NE, Demoruelle MK, Harley JB, Edison JD, Norris JA, Robinson WH, Deane KD, James JA, Holers VM. Antibody Responses to Epstein-Barr Virus in the Preclinical Period of Rheumatoid Arthritis Suggest the Presence of Increased Viral Reactivation Cycles. Arthritis Rheumatol. 2022 04; 74(4):597-603. PMID: 34605217.
      View in: PubMed
    8. Okamoto Y, Devoe S, Seto N, Minarchick V, Wilson T, Rothfuss HM, Mohning MP, Arbet J, Kroehl M, Visser A, August J, Thomas SM, Charry LL, Fleischer C, Feser ML, Frazer-Abel AA, Norris JM, Cherrington BD, Janssen WJ, Kaplan MJ, Deane KD, Holers VM, Demoruelle MK. Association of Sputum Neutrophil Extracellular Trap Subsets With IgA Anti-Citrullinated Protein Antibodies in Subjects at Risk for Rheumatoid Arthritis. Arthritis Rheumatol. 2022 01; 74(1):38-48. PMID: 34369110.
      View in: PubMed
    9. Hughes-Austin JM, Ix JH, Ward SR, Weisman MH, ODell JR, Mikuls TR, Buckner JH, Gregersen PK, Keating RM, Demoruelle MK, Deane KD, Holers VM, Norris JM. Evaluating associations of joint swelling, joint stiffness and joint pain with physical activity in first-degree relatives of patients with rheumatoid arthritis: Studies of the Aetiology of Rheumatoid Arthritis (SERA), a prospective cohort study. BMJ Open. 2021 09 14; 11(9):e050883. PMID: 34521672.
      View in: PubMed
    10. Wahid AA, Dunphy RW, Macpherson A, Gibson BG, Kulik L, Whale K, Back C, Hallam TM, Alkhawaja B, Martin RL, Meschede I, Laabei M, Lawson ADG, Holers VM, Watts AG, Crennell SJ, Harris CL, Marchbank KJ, van den Elsen JMH. Insights Into the Structure-Function Relationships of Dimeric C3d Fragments. Front Immunol. 2021; 12:714055. PMID: 34434196.
      View in: PubMed
    11. Bettner LF, Peterson RA, Bergstedt DT, Kelmenson LB, Demoruelle MK, Mikuls TR, Edison JD, Parish MC, Feser ML, Frazer-Abel AA, Moss LK, Mahler M, Holers VM, Deane KD. Combinations of Anticyclic Citrullinated Protein Antibody, Rheumatoid Factor, and Serum Calprotectin Positivity Are Associated With the Diagnosis of Rheumatoid Arthritis Within 3 Years. ACR Open Rheumatol. 2021 Oct; 3(10):684-689. PMID: 34288565.
      View in: PubMed
    12. Demoruelle MK, Wang H, Davis RL, Visser A, Hoang J, Norris JM, Holers VM, Deane KD, Darrah E. Anti-peptidylarginine deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis. Arthritis Res Ther. 2021 06 06; 23(1):163. PMID: 34092252.
      View in: PubMed
    13. Mangalea MR, Paez-Espino D, Kieft K, Chatterjee A, Chriswell ME, Seifert JA, Feser ML, Demoruelle MK, Sakatos A, Anantharaman K, Deane KD, Kuhn KA, Holers VM, Duerkop BA. Individuals at risk for rheumatoid arthritis harbor differential intestinal bacteriophage communities with distinct metabolic potential. Cell Host Microbe. 2021 05 12; 29(5):726-739.e5. PMID: 33957082.
      View in: PubMed
    14. Nigrovic PA, Colbert RA, Holers VM, Ozen S, Ruperto N, Thompson SD, Wedderburn LR, Yeung RSM, Martini A. Publisher Correction: Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev Rheumatol. 2021 May; 17(5):306. PMID: 33782593.
      View in: PubMed
    15. Polinski KJ, Bemis EA, Yang F, Crume T, Demoruelle MK, Feser M, Seifert J, O'Dell JR, Mikuls TR, Weisman MH, Gregersen PK, Keating RM, Buckner J, Reisdorph N, Deane KD, Clare-Salzler M, Holers VM, Norris JM. Association of Lipid Mediators With Development of Future Incident Inflammatory Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population. Arthritis Rheumatol. 2021 06; 73(6):955-962. PMID: 33381911.
      View in: PubMed
    16. Wagner BD, Patnaik JL, Palestine AG, Frazer-Abel AA, Baldermann R, Holers VM, Mathias MT, Mandava N, Lynch AM. Association of Systemic Inflammatory Factors with Progression to Advanced Age-related Macular Degeneration. Ophthalmic Epidemiol. 2022 04; 29(2):139-148. PMID: 33827374.
      View in: PubMed
    17. Nigrovic PA, Colbert RA, Holers VM, Ozen S, Ruperto N, Thompson SD, Wedderburn LR, Yeung RSM, Martini A. Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev Rheumatol. 2021 05; 17(5):257-269. PMID: 33731872.
      View in: PubMed
    18. Polinski KJ, Armstrong M, Manke J, Seifert J, Crume T, Yang F, Clare-Salzler M, Holers VM, Reisdorph N, Norris JM. Collection and Storage of Human Plasma for Measurement of Oxylipins. Metabolites. 2021 Feb 26; 11(3). PMID: 33652624.
      View in: PubMed
    19. Li C, Patel K, Tu Z, Yang X, Kulik L, Alawieh A, Allen P, Cheng Q, Wallace C, Kilkenny J, Kwon J, Gibney B, Cantu E, Sharma A, Pipkin M, Machuca T, Emtiazjoo A, Goddard M, Holers VM, Nadig S, Christie J, Tomlinson S, Atkinson C. A novel injury site-natural antibody targeted complement inhibitor protects against lung transplant injury. Am J Transplant. 2021 06; 21(6):2067-2078. PMID: 33210808.
      View in: PubMed
    20. Juge PA, Lee JS, Lau J, Kawano-Dourado L, Rojas Serrano J, Sebastiani M, Koduri G, Matteson E, Bonfiglioli K, Sawamura M, Kairalla R, Cavagna L, Bozzalla Cassione E, Manfredi A, Mejia M, Rodríguez-Henriquez P, González-Pérez MI, Falfán-Valencia R, Buendia-Roldán I, Pérez-Rubio G, Ebstein E, Gazal S, Borie R, Ottaviani S, Kannengiesser C, Wallaert B, Uzunhan Y, Nunes H, Valeyre D, Saidenberg-Kermanac'h N, Boissier MC, Wemeau-Stervinou L, Flipo RM, Marchand-Adam S, Richette P, Allanore Y, Dromer C, Truchetet ME, Richez C, Schaeverbeke T, Lioté H, Thabut G, Deane KD, Solomon JJ, Doyle T, Ryu JH, Rosas I, Holers VM, Boileau C, Debray MP, Porcher R, Schwartz DA, Vassallo R, Crestani B, Dieudé P. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2021 02; 57(2). PMID: 32646919.
      View in: PubMed
    21. Okamato Y, Ghosh T, Okamoto T, Schuyler RP, Seifert J, Charry LL, Visser A, Feser M, Fleischer C, Pedrick C, August J, Moss L, Bemis EA, Norris JM, Kuhn KA, Demoruelle MK, Deane KD, Ghosh D, Holers VM, Hsieh EWY. Subjects at-risk for future development of rheumatoid arthritis demonstrate a PAD4-and TLR-dependent enhanced histone H3 citrullination and proinflammatory cytokine production in CD14hi monocytes. J Autoimmun. 2021 02; 117:102581. PMID: 33310262.
      View in: PubMed
    22. Polinski KJ, Bemis EA, Feser M, Seifert J, Demoruelle MK, Striebich CC, Brake S, O'Dell JR, Mikuls TR, Weisman MH, Gregersen PK, Keating RM, Buckner J, Nicassio P, Holers VM, Deane KD, Norris JM. Perceived Stress and Inflammatory Arthritis: A Prospective Investigation in the Studies of the Etiologies of Rheumatoid Arthritis Cohort. Arthritis Care Res (Hoboken). 2020 12; 72(12):1766-1771. PMID: 31600025.
      View in: PubMed
    23. Banda NK, Tomlinson S, Scheinman RI, Ho N, Ramirez JR, Mehta G, Wang G, Vu VP, Simberg D, Kulik L, Holers VM. C2 IgM Natural Antibody Enhances Inflammation and Its Use in the Recombinant Single Chain Antibody-Fused Complement Inhibitor C2-Crry to Target Therapeutics to Joints Attenuates Arthritis in Mice. Front Immunol. 2020; 11:575154. PMID: 33178202.
      View in: PubMed
    24. Mandava N, Tirado-Gonzalez V, Geiger MD, Patnaik JL, Frazer-Abel A, Lynch AM, Mandava N, Palestine AG, Holers VM, Wagner BD, Sanchez-Santos I, Meizner D, Quiroz-Mercado H, Smith JM. Complement Activation in the Vitreous of Patients With Proliferative Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2020 09 01; 61(11):39. PMID: 32965482.
      View in: PubMed
    25. Song YJ, Choi IA, Meylan F, Demoruelle MK, Farley T, Richard AC, Hawley E, Botson J, Hong YJ, Lee EY, Mian SR, Hamilton BC, Thiele GM, Mikuls TR, Gara N, Ward CD, Lamberth S, Deane KD, Heller T, Ward MM, Lee DM, Migone TS, Stohl W, O'Dell JR, Norris JM, Holers VM, Gregersen P, Song YW, Siegel RM. Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF. Arthritis Res Ther. 2020 05 07; 22(1):106. PMID: 32381123.
      View in: PubMed
    26. James JA, Guthridge JM, Chen H, Lu R, Bourn RL, Bean K, Munroe ME, Smith M, Chakravarty E, Baer AN, Noaiseh G, Parke A, Boyle K, Keyes-Elstein L, Coca A, Utset T, Genovese MC, Pascual V, Utz PJ, Holers VM, Deane KD, Sivils KL, Aberle T, Wallace DJ, McNamara J, Franchimont N, St Clair EW. Unique Sjögren's syndrome patient subsets defined by molecular features. Rheumatology (Oxford). 2020 04 01; 59(4):860-868. PMID: 31497844.
      View in: PubMed
    27. Ayyappan P, Harms RZ, Seifert JA, Bemis EA, Feser ML, Deane KD, Demoruelle MK, Mikuls TR, Holers VM, Sarvetnick NE. Heightened Levels of Antimicrobial Response Factors in Patients With Rheumatoid Arthritis. Front Immunol. 2020; 11:427. PMID: 32265916.
      View in: PubMed
    28. Huizinga TW, Holers VM, Anolik J, Brenner MB, Buckley CD, Bykerk V, Connolly SE, Deane KD, Guo J, Hodge M, Hoffmann S, Nestle F, Pitzalis C, Raychaudhuri S, Yamamoto K, Li Z, Klareskog L. Disruptive innovation in rheumatology: new networks of global public-private partnerships are needed to take advantage of scientific progress. Ann Rheum Dis. 2020 05; 79(5):553-555. PMID: 32139419.
      View in: PubMed
    29. Holers VM, Borodovsky A, Scheinman RI, Ho N, Ramirez JR, Dobó J, Gál P, Lindenberger J, Hansen AG, Desai D, Pihl R, Thiel S, Banda NK. Key Components of the Complement Lectin Pathway Are Not Only Required for the Development of Inflammatory Arthritis but Also Regulate the Transcription of Factor D. Front Immunol. 2020; 11:201. PMID: 32153567.
      View in: PubMed
    30. Frid MG, McKeon BA, Thurman JM, Maron BA, Li M, Zhang H, Kumar S, Sullivan T, Laskowsky J, Fini MA, Hu S, Tuder RM, Gandjeva A, Wilkins MR, Rhodes CJ, Ghataorhe P, Leopold JA, Wang RS, Holers VM, Stenmark KR. Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension. Am J Respir Crit Care Med. 2020 01 15; 201(2):224-239. PMID: 31545648.
      View in: PubMed
    31. Lynch AM, Palestine AG, Wagner BD, Patnaik JL, Frazier-Abel AA, Mathias MT, Siringo FS, Holers VM, Mandava N. Complement factors and reticular pseudodrusen in intermediate age-related macular degeneration staged by multimodal imaging. BMJ Open Ophthalmol. 2020; 5(1):e000361. PMID: 32509962.
      View in: PubMed
    32. Kelmenson LB, Wagner BD, McNair BK, Frazer-Abel A, Demoruelle MK, Bergstedt DT, Feser ML, Moss LK, Parish MC, Mewshaw EA, Mikuls TR, Edison JD, Holers VM, Deane KD. Timing of Elevations of Autoantibody Isotypes Prior to Diagnosis of Rheumatoid Arthritis. Arthritis Rheumatol. 2020 02; 72(2):251-261. PMID: 31464042.
      View in: PubMed
    33. Kulik L, Laskowski J, Renner B, Woolaver R, Zhang L, Lyubchenko T, You Z, Thurman JM, Holers VM. Targeting the Immune Complex-Bound Complement C3d Ligand as a Novel Therapy for Lupus. J Immunol. 2019 12 15; 203(12):3136-3147. PMID: 31732528.
      View in: PubMed
    34. Mastellos DC, Blom AM, Connolly ES, Daha MR, Geisbrecht BV, Ghebrehiwet B, Gros P, Hajishengallis G, Holers VM, Huber-Lang M, Kinoshita T, Mollnes TE, Montgomery RA, Morgan BP, Nilsson B, Pio R, Ricklin D, Risitano AM, Taylor RP, Mantovani A, Ioannidis JPA, Lambris JD. Author Correction: 'Stealth' corporate innovation: an emerging threat for therapeutic drug development. Nat Immunol. 2019 Nov; 20(11):1556. PMID: 31605100.
      View in: PubMed
    35. Mastellos DC, Blom AM, Connolly ES, Daha MR, Geisbrecht BV, Ghebrehiwet B, Gros P, Hajishengallis G, Holers VM, Huber-Lang M, Kinoshita T, Mollnes TE, Montgomery RA, Morgan BP, Nilsson B, Pio R, Ricklin D, Risitano AM, Taylor RP, Mantovani A, Ioannidis JPA, Lambris JD. 'Stealth' corporate innovation: an emerging threat for therapeutic drug development. Nat Immunol. 2019 11; 20(11):1409-1413. PMID: 31562490.
      View in: PubMed
    36. Slight-Webb S, Bourn RL, Holers VM, James JA. Shared and unique immune alterations in pre-clinical autoimmunity. Curr Opin Immunol. 2019 12; 61:60-68. PMID: 31557691.
      View in: PubMed
    37. Lynch AM, Mandava N, Patnaik JL, Frazer-Abel AA, Wagner BD, Palestine AG, Mathias MT, Siringo FS, Cathcart JN, Holers VM. Systemic activation of the complement system in patients with advanced age-related macular degeneration. Eur J Ophthalmol. 2020 Sep; 30(5):1061-1068. PMID: 31203676.
      View in: PubMed
    38. Raza K, Holers VM, Gerlag D. Nomenclature for the Phases of the Development of Rheumatoid Arthritis. Clin Ther. 2019 07; 41(7):1279-1285. PMID: 31196657.
      View in: PubMed
    39. Deane KD, Holers VM. The Natural History of Rheumatoid Arthritis. Clin Ther. 2019 07; 41(7):1256-1269. PMID: 31196652.
      View in: PubMed
    40. Hernandez G, Mills TS, Rabe JL, Chavez JS, Kuldanek S, Kirkpatrick G, Noetzli L, Jubair WK, Zanche M, Myers JR, Stevens BM, Fleenor CJ, Adane B, Dinarello CA, Ashton J, Jordan CT, Di Paola J, Hagman JR, Holers VM, Kuhn KA, Pietras EM. Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis. Haematologica. 2020 03; 105(3):585-597. PMID: 31101752.
      View in: PubMed
    41. Zhang F, Wei K, Slowikowski K, Fonseka CY, Rao DA, Kelly S, Goodman SM, Tabechian D, Hughes LB, Salomon-Escoto K, Watts GFM, Jonsson AH, Rangel-Moreno J, Meednu N, Rozo C, Apruzzese W, Eisenhaure TM, Lieb DJ, Boyle DL, Mandelin AM, Boyce BF, DiCarlo E, Gravallese EM, Gregersen PK, Moreland L, Firestein GS, Hacohen N, Nusbaum C, Lederer JA, Perlman H, Pitzalis C, Filer A, Holers VM, Bykerk VP, Donlin LT, Anolik JH, Brenner MB, Raychaudhuri S. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol. 2019 07; 20(7):928-942. PMID: 31061532.
      View in: PubMed
    42. Gifford G, Vu VP, Banda NK, Holers VM, Wang G, Groman EV, Backos D, Scheinman R, Moghimi SM, Simberg D. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55. J Control Release. 2019 05 28; 302:181-189. PMID: 30974134.
      View in: PubMed
    43. Stathopoulos P, Chastre A, Waters P, Irani S, Fichtner ML, Benotti ES, Guthridge JM, Seifert J, Nowak RJ, Buckner JH, Holers VM, James JA, Hafler DA, O'Connor KC. Autoantibodies against Neurologic Antigens in Nonneurologic Autoimmunity. J Immunol. 2019 04 15; 202(8):2210-2219. PMID: 30824481.
      View in: PubMed
    44. Holers VM, Demoruelle MK, Kuhn KA, Buckner JH, Robinson WH, Okamoto Y, Norris JM, Deane KD. Rheumatoid arthritis and the mucosal origins hypothesis: protection turns to destruction. Nat Rev Rheumatol. 2018 09; 14(9):542-557. PMID: 30111803.
      View in: PubMed
    45. Banda NK, Desai D, Scheinman RI, Pihl R, Sekine H, Fujita T, Sharma V, Hansen AG, Garred P, Thiel S, Borodovsky A, Holers VM. Targeting of Liver Mannan-Binding Lectin-Associated Serine Protease-3 with RNA Interference Ameliorates Disease in a Mouse Model of Rheumatoid Arthritis. Immunohorizons. 2018 Sep; 2(8):274-295. PMID: 30417171.
      View in: PubMed
    46. Hughes-Austin JM, Deane KD, Giles JT, Derber LA, Zerbe GO, Dabelea DM, Sokolove J, Robinson WH, Holers VM, Norris JM. Plasma adiponectin levels are associated with circulating inflammatory cytokines in autoantibody positive first-degree relatives of rheumatoid arthritis patients. PLoS One. 2018; 13(6):e0199578. PMID: 29940013.
      View in: PubMed
    47. Holers VM, Banda NK. Complement in the Initiation and Evolution of Rheumatoid Arthritis. Front Immunol. 2018; 9:1057. PMID: 29892280.
      View in: PubMed
    48. Lingampalli N, Sokolove J, Lahey LJ, Edison JD, Gilliland WR, Holers VM, Deane KD, Robinson WH. Combination of anti-citrullinated protein antibodies and rheumatoid factor is associated with increased systemic inflammatory mediators and more rapid progression from preclinical to clinical rheumatoid arthritis. Clin Immunol. 2018 10; 195:119-126. PMID: 29842946.
      View in: PubMed
    49. Okamoto T, Mathai SK, Hennessy CE, Hancock LA, Walts AD, Stefanski AL, Brown KK, Lynch DA, Cosgrove GP, Groshong SD, Cool CD, Schwarz MI, Banda NK, Thurman JM, Yang IV, Holers VM, Schwartz DA. The relationship between complement C3 expression and the MUC5B genotype in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2018 07 01; 315(1):L1-L10. PMID: 29565179.
      View in: PubMed
    50. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 29237149.
      View in: PubMed
    51. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 29996944.
      View in: PubMed
    52. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 30006493.
      View in: PubMed
    53. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 30060927.
      View in: PubMed
    54. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 28217918.
      View in: PubMed
    55. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 28739878.
      View in: PubMed
    56. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 26510395.
      View in: PubMed
    57. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 25979851.
      View in: PubMed
    58. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 27814381.
      View in: PubMed
    59. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 27190099.
      View in: PubMed
    60. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 28182854.
      View in: PubMed
    61. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 29781231.
      View in: PubMed
    62. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 30952617.
      View in: PubMed
    63. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 30988128.
      View in: PubMed
    64. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 31207549.
      View in: PubMed
    65. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 32602263.
      View in: PubMed
    66. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 32776474.
      View in: PubMed
    67. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 32928740.
      View in: PubMed
    68. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 33740660.
      View in: PubMed
    69. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 34362746.
      View in: PubMed
    70. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 35037713.
      View in: PubMed
    71. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 35036032.
      View in: PubMed
    72. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 35143312.
      View in: PubMed
    73. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 35420644.
      View in: PubMed
    74. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 34459222.
      View in: PubMed
    75. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 35536990.
      View in: PubMed
    76. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 35644031.
      View in: PubMed
    77. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 18374982.
      View in: PubMed
    78. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 9083278.
      View in: PubMed
    79. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 2448783.
      View in: PubMed
    80. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 10408385.
      View in: PubMed
    81. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 2145366.
      View in: PubMed
    82. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 14636948.
      View in: PubMed
    83. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 7737272.
      View in: PubMed
    84. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 10946257.
      View in: PubMed
    85. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 15086380.
      View in: PubMed
    86. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 9605124.
      View in: PubMed
    87. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 17974596.
      View in: PubMed
    88. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 23337717.
      View in: PubMed
    89. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 12244142.
      View in: PubMed
    90. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 20810984.
      View in: PubMed
    91. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 1730912.
      View in: PubMed
    92. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 16375923.
      View in: PubMed
    93. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 1378280.
      View in: PubMed
    94. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 7589142.
      View in: PubMed
    95. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 20332377.
      View in: PubMed
    96. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 11739509.
      View in: PubMed
    97. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 8409455.
      View in: PubMed
    98. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 19252818.
      View in: PubMed
    99. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 16444293.
      View in: PubMed
    100. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 12379621.
      View in: PubMed
    101. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 22365785.
      View in: PubMed
    102. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 14500265.
      View in: PubMed
    103. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 19164292.
      View in: PubMed
    104. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 15086460.
      View in: PubMed
    105. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 11907125.
      View in: PubMed
    106. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 19703021.
      View in: PubMed
    107. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 11698449.
      View in: PubMed
    108. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 12902517.
      View in: PubMed
    109. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 22492944.
      View in: PubMed
    110. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 19625656.
      View in: PubMed
    111. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 21943708.
      View in: PubMed
    112. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 22915618.
      View in: PubMed
    113. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 16876864.
      View in: PubMed
    114. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 12813023.
      View in: PubMed
    115. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 2573727.
      View in: PubMed
    116. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 18821684.
      View in: PubMed
    117. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 17475881.
      View in: PubMed
    118. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 9862679.
      View in: PubMed
    119. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 22183986.
      View in: PubMed
    120. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 16172256.
      View in: PubMed
    121. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 20496417.
      View in: PubMed
    122. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 17522263.
      View in: PubMed
    123. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 15749857.
      View in: PubMed
    124. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 22309197.
      View in: PubMed
    125. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 1455049.
      View in: PubMed
    126. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 16611864.
      View in: PubMed
    127. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 17237432.
      View in: PubMed
    128. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 23319740.
      View in: PubMed
    129. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 16467447.
      View in: PubMed
    130. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 19820137.
      View in: PubMed
    131. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 17915095.
      View in: PubMed
    132. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 17925391.
      View in: PubMed
    133. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 10642554.
      View in: PubMed
    134. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 19359041.
      View in: PubMed
    135. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 21860027.
      View in: PubMed
    136. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 11433344.
      View in: PubMed
    137. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 22662108.
      View in: PubMed
    138. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 20533289.
      View in: PubMed
    139. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 16785534.
      View in: PubMed
    140. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 19187965.
      View in: PubMed
    141. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 3161944.
      View in: PubMed
    142. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 22542119.
      View in: PubMed
    143. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 11012892.
      View in: PubMed
    144. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 11387479.
      View in: PubMed
    145. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 18025232.
      View in: PubMed
    146. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 16950392.
      View in: PubMed
    147. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 20558730.
      View in: PubMed
    148. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 9574562.
      View in: PubMed
    149. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 23728171.
      View in: PubMed
    150. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 23686569.
      View in: PubMed
    151. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 23927533.
      View in: PubMed
    152. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 24247116.
      View in: PubMed
    153. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 23817979.
      View in: PubMed
    154. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 24172683.
      View in: PubMed
    155. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 23492764.
      View in: PubMed
    156. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 25437280.
      View in: PubMed
    157. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 25339123.
      View in: PubMed
    158. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 25825397.
      View in: PubMed
    159. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 24449338.
      View in: PubMed
    160. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 25988241.
      View in: PubMed
    161. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 26488074.
      View in: PubMed
    162. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 26224307.
      View in: PubMed
    163. Mihai S, Hirose M, Wang Y, Thurman JM, Holers VM, Morgan BP, Köhl J, Zillikens D, Ludwig RJ, Nimmerjahn F. Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice. Front Immunol. 2018; 9:535. PMID: 29616034.
      View in: PubMed
    164. Demoruelle MK, Bowers E, Lahey LJ, Sokolove J, Purmalek M, Seto NL, Weisman MH, Norris JM, Kaplan MJ, Holers VM, Robinson WH, Deane KD. Antibody Responses to Citrullinated and Noncitrullinated Antigens in the Sputum of Subjects With Rheumatoid Arthritis and Subjects at Risk for Development of Rheumatoid Arthritis. Arthritis Rheumatol. 2018 04; 70(4):516-527. PMID: 29266801.
      View in: PubMed
    165. Goetz L, Laskowski J, Renner B, Pickering MC, Kulik L, Klawitter J, Stites E, Christians U, van der Vlag J, Ravichandran K, Holers VM, Thurman JM. Complement factor H protects mice from ischemic acute kidney injury but is not critical for controlling complement activation by glomerular IgM. Eur J Immunol. 2018 05; 48(5):791-802. PMID: 29389016.
      View in: PubMed
    166. Gan RW, Bemis EA, Demoruelle MK, Striebich CC, Brake S, Feser ML, Moss L, Clare-Salzler M, Holers VM, Deane KD, Norris JM. The association between omega-3 fatty acid biomarkers and inflammatory arthritis in an anti-citrullinated protein antibody positive population. Rheumatology (Oxford). 2017 12 01; 56(12):2229-2236. PMID: 29029330.
      View in: PubMed
    167. Antonioli AH, White J, Crawford F, Renner B, Marchbank KJ, Hannan JP, Thurman JM, Marrack P, Holers VM. Modulation of the Alternative Pathway of Complement by Murine Factor H-Related Proteins. J Immunol. 2018 01 01; 200(1):316-326. PMID: 29187587.
      View in: PubMed
    168. Thurman JM, Frazer-Abel A, Holers VM. The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases. Arthritis Rheumatol. 2017 11; 69(11):2102-2113. PMID: 28732131.
      View in: PubMed
    169. He YG, Pappworth IY, Rossbach A, Paulin J, Mavimba T, Hayes C, Kulik L, Holers VM, Knight AM, Marchbank KJ. A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice. Immunobiology. 2018 01; 223(1):125-134. PMID: 29017821.
      View in: PubMed
    170. Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2017 02; 31(1):3-18. PMID: 29221595.
      View in: PubMed
    171. Birru Talabi M, Mackey RH, Kuller LH, Dorman JS, Deane KD, Robinson WH, Walitt BT, Chang Y, Holers VM, Liu S, Moreland LW. Human Leukocyte Antigen Shared Epitope and Inflammation, Cardiovascular Disease, Cancer, and Mortality Among Postmenopausal Women in the Women's Health Initiative Rheumatoid Arthritis Study. Am J Epidemiol. 2017 Jul 15; 186(2):245-254. PMID: 28459968.
      View in: PubMed
    172. Narang A, Qiao F, Atkinson C, Zhu H, Yang X, Kulik L, Holers VM, Tomlinson S. Natural IgM antibodies that bind neoepitopes exposed as a result of spinal cord injury , drive secondary injury by activating complement. J Neuroinflammation. 2017 06 19; 14(1):120. PMID: 28629465.
      View in: PubMed
    173. Willis VC, Banda NK, Cordova KN, Chandra PE, Robinson WH, Cooper DC, Lugo D, Mehta G, Taylor S, Tak PP, Prinjha RK, Lewis HD, Holers VM. Protein arginine deiminase 4 inhibition is sufficient for the amelioration of collagen-induced arthritis. Clin Exp Immunol. 2017 05; 188(2):263-274. PMID: 28128853.
      View in: PubMed
    174. Wang G, Griffin JI, Inturi S, Brenneman B, Banda NK, Holers VM, Moghimi SM, Simberg D. In Vitro and In Vivo Differences in Murine Third Complement Component (C3) Opsonization and Macrophage/Leukocyte Responses to Antibody-Functionalized Iron Oxide Nanoworms. Front Immunol. 2017; 8:151. PMID: 28239384.
      View in: PubMed
    175. Chen F, Wang G, Griffin JI, Brenneman B, Banda NK, Holers VM, Backos DS, Wu L, Moghimi SM, Simberg D. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. Nat Nanotechnol. 2017 05; 12(4):387-393. PMID: 27992410.
      View in: PubMed
    176. Chang HH, Liu GY, Dwivedi N, Sun B, Okamoto Y, Kinslow JD, Deane KD, Demoruelle MK, Norris JM, Thompson PR, Sparks JA, Rao DA, Karlson EW, Hung HC, Holers VM, Ho IC. A molecular signature of preclinical rheumatoid arthritis triggered by dysregulated PTPN22. JCI Insight. 2016 Oct 20; 1(17):e90045. PMID: 27777982.
      View in: PubMed
    177. Wang G, Chen F, Banda NK, Holers VM, Wu L, Moghimi SM, Simberg D. Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles Is Not Affected by Dextran/Fe Ratio, Hydroxyl Modifications, and Crosslinking. Front Immunol. 2016; 7:418. PMID: 27777575.
      View in: PubMed
    178. Banda NK, Acharya S, Scheinman RI, Mehta G, Coulombe M, Takahashi M, Sekine H, Thiel S, Fujita T, Holers VM. Mannan-Binding Lectin-Associated Serine Protease 1/3 Cleavage of Pro-Factor D into Factor D In Vivo and Attenuation of Collagen Antibody-Induced Arthritis through Their Targeted Inhibition by RNA Interference-Mediated Gene Silencing. J Immunol. 2016 11 01; 197(9):3680-3694. PMID: 27707997.
      View in: PubMed
    179. Kinslow JD, Blum LK, Deane KD, Demoruelle MK, Okamoto Y, Parish MC, Kongpachith S, Lahey LJ, Norris JM, Robinson WH, Holers VM. Elevated IgA Plasmablast Levels in Subjects at Risk of Developing Rheumatoid Arthritis. Arthritis Rheumatol. 2016 10; 68(10):2372-83. PMID: 27273876.
      View in: PubMed
    180. Holers VM, Tomlinson S, Kulik L, Atkinson C, Rohrer B, Banda N, Thurman JM. New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities. Semin Immunol. 2016 06; 28(3):260-7. PMID: 27282113.
      View in: PubMed
    181. Laskowski J, Renner B, Le Quintrec M, Panzer S, Hannan JP, Ljubanovic D, Ruseva MM, Borza DB, Antonioli AH, Pickering MC, Holers VM, Thurman JM. Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury. Kidney Int. 2016 07; 90(1):109-22. PMID: 27165610.
      View in: PubMed
    182. Rich MC, Keene CN, Neher MD, Johnson K, Yu ZX, Ganivet A, Holers VM, Stahel PF. Site-targeted complement inhibition by a complement receptor 2-conjugated inhibitor (mTT30) ameliorates post-injury neuropathology in mouse brains. Neurosci Lett. 2016 Mar 23; 617:188-94. PMID: 26892188.
      View in: PubMed
    183. Renner B, Tong HH, Laskowski J, Jonscher K, Goetz L, Woolaver R, Hannan J, Li YX, Hourcade D, Pickering MC, Holers VM, Thurman JM. Annexin A2 Enhances Complement Activation by Inhibiting Factor H. J Immunol. 2016 Feb 01; 196(3):1355-65. PMID: 26729803.
      View in: PubMed
    184. Lynch AM, Wagner BD, Deterding RR, Giclas PC, Gibbs RS, Janoff EN, Holers VM, Santoro NF. The relationship of circulating proteins in early pregnancy with preterm birth. Am J Obstet Gynecol. 2016 Apr; 214(4):517.e1-517.e8. PMID: 26576488.
      View in: PubMed
    185. Gan RW, Young KA, Zerbe GO, Demoruelle MK, Weisman MH, Buckner JH, Gregersen PK, Mikuls TR, O'Dell JR, Keating RM, Clare-Salzler MJ, Deane KD, Holers VM, Norris JM. Lower omega-3 fatty acids are associated with the presence of anti-cyclic citrullinated peptide autoantibodies in a population at risk for future rheumatoid arthritis: a nested case-control study. Rheumatology (Oxford). 2016 Feb; 55(2):367-76. PMID: 26370400.
      View in: PubMed
    186. Panzer SE, Laskowski J, Renner B, Kulik L, Ljubanovic D, Huber KM, Zhong W, Pickering MC, Holers VM, Thurman JM. IgM exacerbates glomerular disease progression in complement-induced glomerulopathy. Kidney Int. 2015 Sep; 88(3):528-37. PMID: 25945405.
      View in: PubMed
    187. Mehta G, Scheinman RI, Holers VM, Banda NK. A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA. J Immunol. 2015 Jun 01; 194(11):5446-54. PMID: 25917104.
      View in: PubMed
    188. Cruickshank MN, Dods J, Taylor RL, Karimi M, Fenwick EJ, Quail EA, Rea AJ, Holers VM, Abraham LJ, Ulgiati D. Analysis of tandem E-box motifs within human Complement receptor 2 (CR2/CD21) promoter reveals cell specific roles for RP58, E2A, USF and localized chromatin accessibility. Int J Biochem Cell Biol. 2015 Jul; 64:107-19. PMID: 25817480.
      View in: PubMed
    189. Kulik L, Hewitt FB, Willis VC, Rodriguez R, Tomlinson S, Holers VM. A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and disease. Mol Immunol. 2015 Feb; 63(2):479-88. PMID: 25457881.
      View in: PubMed
    190. Gan RW, Trouw LA, Shi J, Toes RE, Huizinga TW, Demoruelle MK, Kolfenbach JR, Zerbe GO, Deane KD, Edison JD, Gilliland WR, Norris JM, Holers VM. Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis. J Rheumatol. 2015 Apr; 42(4):572-9. PMID: 25593232.
      View in: PubMed
    191. Banda NK, Mehta G, Kjaer TR, Takahashi M, Schaack J, Morrison TE, Thiel S, Arend WP, Holers VM. Essential role for the lectin pathway in collagen antibody-induced arthritis revealed through use of adenovirus programming complement inhibitor MAp44 expression. J Immunol. 2014 Sep 01; 193(5):2455-68. PMID: 25070856.
      View in: PubMed
    192. Yui J, Holers VM, Yang S, Wu HM, Cataland SR. Clinical utility of complement biomarkers in the diagnosis and treatment of acute thrombotic microangiopathies. Br J Haematol. 2014 Dec; 167(5):697-8. PMID: 25040791.
      View in: PubMed
    193. Neher MD, Rich MC, Keene CN, Weckbach S, Bolden AL, Losacco JT, Patane J, Flierl MA, Kulik L, Holers VM, Stahel PF. Deficiency of complement receptors CR2/CR1 in Cr2?/? mice reduces the extent of secondary brain damage after closed head injury. J Neuroinflammation. 2014 May 24; 11:95. PMID: 24885042.
      View in: PubMed
    194. Cataland SR, Holers VM, Geyer S, Yang S, Wu HM. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood. 2014 Jun 12; 123(24):3733-8. PMID: 24695849.
      View in: PubMed
    195. Kuller LH, Mackey RH, Walitt BT, Deane KD, Holers VM, Robinson WH, Sokolove J, Chang Y, Liu S, Parks CG, Wright NC, Moreland LW. Determinants of mortality among postmenopausal women in the women's health initiative who report rheumatoid arthritis. Arthritis Rheumatol. 2014 Mar; 66(3):497-507. PMID: 24574208.
      View in: PubMed
    196. Kuller LH, Mackey RH, Walitt BT, Deane KD, Holers VM, Robinson WH, Sokolove J, Chang Y, Moreland LW. Rheumatoid arthritis in the Women's Health Initiative: methods and baseline evaluation. Am J Epidemiol. 2014 Apr 01; 179(7):917-26. PMID: 24569640.
      View in: PubMed
    197. Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol. 2014; 32:433-59. PMID: 24499275.
      View in: PubMed
    198. Holers VM. Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis. Curr Opin Immunol. 2013 Dec; 25(6):728-35. PMID: 24215742.
      View in: PubMed
    199. Young KA, Deane KD, Derber LA, Hughes-Austin JM, Wagner CA, Sokolove J, Weisman MH, Buckner JH, Mikuls TR, O'Dell JR, Keating RM, Gregersen PK, Robinson WH, Holers VM, Norris JM. Relatives without rheumatoid arthritis show reactivity to anti-citrullinated protein/peptide antibodies that are associated with arthritis-related traits: studies of the etiology of rheumatoid arthritis. Arthritis Rheum. 2013 Aug; 65(8):1995-2004. PMID: 23754702.
      View in: PubMed
    200. Keith RC, Sokolove J, Edelman BL, Lahey L, Redente EF, Holers VM, Sakaguchi S, Robinson WH, Riches DW. Testosterone is protective in the sexually dimorphic development of arthritis and lung disease in SKG mice. Arthritis Rheum. 2013 Jun; 65(6):1487-93. PMID: 23529475.
      View in: PubMed
    201. Whitcup SM, Sodhi A, Atkinson JP, Holers VM, Sinha D, Rohrer B, Dick AD. The role of the immune response in age-related macular degeneration. Int J Inflam. 2013; 2013:348092. PMID: 23762772.
      View in: PubMed
    202. Arend WP, Mehta G, Antonioli AH, Takahashi M, Takahashi K, Stahl GL, Holers VM, Banda NK. Roles of adipocytes and fibroblasts in activation of the alternative pathway of complement in inflammatory arthritis in mice. J Immunol. 2013 Jun 15; 190(12):6423-33. PMID: 23650618.
      View in: PubMed
    203. Thurman JM, Kulik L, Orth H, Wong M, Renner B, Sargsyan SA, Mitchell LM, Hourcade DE, Hannan JP, Kovacs JM, Coughlin B, Woodell AS, Pickering MC, Rohrer B, Holers VM. Detection of complement activation using monoclonal antibodies against C3d. J Clin Invest. 2013 May; 123(5):2218-30. PMID: 23619360.
      View in: PubMed
    204. Gan RW, Deane KD, Zerbe GO, Demoruelle MK, Weisman MH, Buckner JH, Gregersen PK, Mikuls TR, O'Dell JR, Keating RM, Holers VM, Norris JM. Relationship between air pollution and positivity of RA-related autoantibodies in individuals without established RA: a report on SERA. Ann Rheum Dis. 2013 Dec; 72(12):2002-5. PMID: 23572338.
      View in: PubMed
    205. Joseph K, Kulik L, Coughlin B, Kunchithapautham K, Bandyopadhyay M, Thiel S, Thielens NM, Holers VM, Rohrer B. Oxidative stress sensitizes retinal pigmented epithelial (RPE) cells to complement-mediated injury in a natural antibody-, lectin pathway-, and phospholipid epitope-dependent manner. J Biol Chem. 2013 May 03; 288(18):12753-65. PMID: 23493397.
      View in: PubMed
    206. Banda NK, Mehta G, Ferreira VP, Cortes C, Pickering MC, Pangburn MK, Arend WP, Holers VM. Essential role of surface-bound complement factor H in controlling immune complex-induced arthritis. J Immunol. 2013 Apr 01; 190(7):3560-9. PMID: 23436934.
      View in: PubMed
    207. Strassheim D, Renner B, Panzer S, Fuquay R, Kulik L, Ljubanovic D, Holers VM, Thurman JM. IgM contributes to glomerular injury in FSGS. J Am Soc Nephrol. 2013 Feb; 24(3):393-406. PMID: 23393315.
      View in: PubMed
    208. Holers VM, Rohrer B, Tomlinson S. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv Exp Med Biol. 2013; 735:137-54. PMID: 23402024.
      View in: PubMed
    209. Mikuls TR, Thiele GM, Deane KD, Payne JB, O'Dell JR, Yu F, Sayles H, Weisman MH, Gregersen PK, Buckner JH, Keating RM, Derber LA, Robinson WH, Holers VM, Norris JM. Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis Rheum. 2012 Nov; 64(11):3522-30. PMID: 22736291.
      View in: PubMed
    210. Liubchenko GA, Appleberry HC, Striebich CC, Franklin KE, Derber LA, Holers VM, Lyubchenko T. Rheumatoid arthritis is associated with signaling alterations in naturally occurring autoreactive B-lymphocytes. J Autoimmun. 2013 Feb; 40:111-21. PMID: 23058039.
      View in: PubMed
    211. Asokan R, Banda NK, Szakonyi G, Chen XS, Holers VM. Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE). Mol Immunol. 2013 Jan; 53(1-2):99-110. PMID: 22885687.
      View in: PubMed
    212. Risitano AM, Notaro R, Pascariello C, Sica M, del Vecchio L, Horvath CJ, Fridkis-Hareli M, Selleri C, Lindorfer MA, Taylor RP, Luzzatto L, Holers VM. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood. 2012 Jun 28; 119(26):6307-16. PMID: 22577173.
      View in: PubMed
    213. Weckbach S, Neher M, Losacco JT, Bolden AL, Kulik L, Flierl MA, Bell SE, Holers VM, Stahel PF. Challenging the role of adaptive immunity in neurotrauma: Rag1(-/-) mice lacking mature B and T cells do not show neuroprotection after closed head injury. J Neurotrauma. 2012 Apr 10; 29(6):1233-42. PMID: 22335783.
      View in: PubMed
    214. Li K, Gor J, Holers VM, Storek MJ, Perkins SJ. Solution structure of TT30, a novel complement therapeutic agent, provides insight into its joint binding to complement C3b and C3d. J Mol Biol. 2012 May 04; 418(3-4):248-63. PMID: 22387467.
      View in: PubMed
    215. Banda NK, Hyatt S, Antonioli AH, White JT, Glogowska M, Takahashi K, Merkel TJ, Stahl GL, Mueller-Ortiz S, Wetsel R, Arend WP, Holers VM. Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. J Immunol. 2012 Feb 01; 188(3):1469-78. PMID: 22205026.
      View in: PubMed
    216. Elvington A, Atkinson C, Kulik L, Zhu H, Yu J, Kindy MS, Holers VM, Tomlinson S. Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice. J Immunol. 2012 Feb 01; 188(3):1460-8. PMID: 22198950.
      View in: PubMed
    217. Keith RC, Powers JL, Redente EF, Sergew A, Martin RJ, Gizinski A, Holers VM, Sakaguchi S, Riches DW. A novel model of rheumatoid arthritis-associated interstitial lung disease in SKG mice. Exp Lung Res. 2012 Mar; 38(2):55-66. PMID: 22185348.
      View in: PubMed
    218. Takeda K, Thurman JM, Tomlinson S, Okamoto M, Shiraishi Y, Ferreira VP, Cortes C, Pangburn MK, Holers VM, Gelfand EW. The critical role of complement alternative pathway regulator factor H in allergen-induced airway hyperresponsiveness and inflammation. J Immunol. 2012 Jan 15; 188(2):661-7. PMID: 22174452.
      View in: PubMed
    219. Wang Q, Rozelle AL, Lepus CM, Scanzello CR, Song JJ, Larsen DM, Crish JF, Bebek G, Ritter SY, Lindstrom TM, Hwang I, Wong HH, Punzi L, Encarnacion A, Shamloo M, Goodman SB, Wyss-Coray T, Goldring SR, Banda NK, Thurman JM, Gobezie R, Crow MK, Holers VM, Lee DM, Robinson WH. Identification of a central role for complement in osteoarthritis. Nat Med. 2011 Nov 06; 17(12):1674-9. PMID: 22057346.
      View in: PubMed
    220. Khan MA, Jiang X, Dhillon G, Beilke J, Holers VM, Atkinson C, Tomlinson S, Nicolls MR. CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res. 2011 Nov 11; 109(11):1290-301. PMID: 21998328.
      View in: PubMed
    221. Pappworth IY, Hayes C, Dimmick J, Morgan BP, Holers VM, Marchbank KJ. Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expression. Immunobiology. 2012 Feb; 217(2):147-57. PMID: 21783272.
      View in: PubMed
    222. Renner B, Ferreira VP, Cortes C, Goldberg R, Ljubanovic D, Pangburn MK, Pickering MC, Tomlinson S, Holland-Neidermyer A, Strassheim D, Holers VM, Thurman JM. Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int. 2011 Jul; 80(2):165-73. PMID: 21544060.
      View in: PubMed
    223. Willis VC, Gizinski AM, Banda NK, Causey CP, Knuckley B, Cordova KN, Luo Y, Levitt B, Glogowska M, Chandra P, Kulik L, Robinson WH, Arend WP, Thompson PR, Holers VM. N-a-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol. 2011 Apr 01; 186(7):4396-404. PMID: 21346230.
      View in: PubMed
    224. Kulik L, Chen K, Huber BT, Holers VM. Human complement receptor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study immunoregulatory effects of receptor antagonists. Mol Immunol. 2011 Mar; 48(6-7):883-94. PMID: 21269698.
      View in: PubMed
    225. Rohrer B, Coughlin B, Kunchithapautham K, Long Q, Tomlinson S, Takahashi K, Holers VM. The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization. Mol Immunol. 2011 Mar; 48(6-7):e1-8. PMID: 21257205.
      View in: PubMed
    226. Lynch AM, Gibbs RS, Murphy JR, Giclas PC, Salmon JE, Holers VM. Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstet Gynecol. 2011 Jan; 117(1):75-83. PMID: 21173647.
      View in: PubMed
    227. Navarra SV, Ishimori MI, Uy EA, Hamijoyo L, Sama J, James JA, Holers VM, Weisman MH. Studies of Filipino patients with systemic lupus erythematosus: autoantibody profile of first-degree relatives. Lupus. 2011 Apr; 20(5):537-43. PMID: 21183559.
      View in: PubMed
    228. Edelhauser HF, Rowe-Rendleman CL, Robinson MR, Dawson DG, Chader GJ, Grossniklaus HE, Rittenhouse KD, Wilson CG, Weber DA, Kuppermann BD, Csaky KG, Olsen TW, Kompella UB, Holers VM, Hageman GS, Gilger BC, Campochiaro PA, Whitcup SM, Wong WT. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci. 2010 Nov; 51(11):5403-20. PMID: 20980702.
      View in: PubMed
    229. Deane KD, O'Donnell CI, Hueber W, Majka DS, Lazar AA, Derber LA, Gilliland WR, Edison JD, Norris JM, Robinson WH, Holers VM. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum. 2010 Nov; 62(11):3161-72. PMID: 20597112.
      View in: PubMed
    230. Shaw CD, Storek MJ, Young KA, Kovacs JM, Thurman JM, Holers VM, Hannan JP. Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking. J Mol Biol. 2010 Dec 10; 404(4):697-710. PMID: 20951140.
      View in: PubMed
    231. Banda NK, Takahashi M, Levitt B, Glogowska M, Nicholas J, Takahashi K, Stahl GL, Fujita T, Arend WP, Holers VM. Essential role of complement mannose-binding lectin-associated serine proteases-1/3 in the murine collagen antibody-induced model of inflammatory arthritis. J Immunol. 2010 Nov 01; 185(9):5598-606. PMID: 20870940.
      View in: PubMed
    232. Ercan A, Cui J, Chatterton DE, Deane KD, Hazen MM, Brintnell W, O'Donnell CI, Derber LA, Weinblatt ME, Shadick NA, Bell DA, Cairns E, Solomon DH, Holers VM, Rudd PM, Lee DM. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum. 2010 Aug; 62(8):2239-48. PMID: 20506563.
      View in: PubMed
    233. Renner B, Coleman K, Goldberg R, Amura C, Holland-Neidermyer A, Pierce K, Orth HN, Molina H, Ferreira VP, Cortes C, Pangburn MK, Holers VM, Thurman JM. The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells. J Immunol. 2010 Sep 01; 185(5):3086-94. PMID: 20675597.
      View in: PubMed
    234. Quan TE, Roman RM, Rudenga BJ, Holers VM, Craft JE. Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells. Arthritis Rheum. 2010 Jun; 62(6):1693-701. PMID: 20178121.
      View in: PubMed
    235. Deane KD, Norris JM, Holers VM. Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. Rheum Dis Clin North Am. 2010 May; 36(2):213-41. PMID: 20510231.
      View in: PubMed
    236. Briggs FB, Ramsay PP, Madden E, Norris JM, Holers VM, Mikuls TR, Sokka T, Seldin MF, Gregersen PK, Criswell LA, Barcellos LF. Supervised machine learning and logistic regression identifies novel epistatic risk factors with PTPN22 for rheumatoid arthritis. Genes Immun. 2010 Apr; 11(3):199-208. PMID: 20090771.
      View in: PubMed
    237. Lynch AM, Murphy JR, Gibbs RS, Levine RJ, Giclas PC, Salmon JE, Holers VM. The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG. 2010 Mar; 117(4):456-62. PMID: 20074261.
      View in: PubMed
    238. Thurman JM, Renner B, Kunchithapautham K, Holers VM, Rohrer B. Aseptic injury to epithelial cells alters cell surface complement regulation in a tissue specific fashion. Adv Exp Med Biol. 2010; 664:151-8. PMID: 20238013.
      View in: PubMed
    239. Rohrer B, Long Q, Coughlin B, Renner B, Huang Y, Kunchithapautham K, Ferreira VP, Pangburn MK, Gilkeson GS, Thurman JM, Tomlinson S, Holers VM. A targeted inhibitor of the complement alternative pathway reduces RPE injury and angiogenesis in models of age-related macular degeneration. Adv Exp Med Biol. 2010; 703:137-49. PMID: 20711712.
      View in: PubMed
    240. Kolfenbach JR, Deane KD, Derber LA, O'Donnell C, Weisman MH, Buckner JH, Gersuk VH, Wei S, Mikuls TR, O'Dell J, Gregersen PK, Keating RM, Norris JM, Holers VM. A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA. Arthritis Rheum. 2009 Dec 15; 61(12):1735-42. PMID: 19950324.
      View in: PubMed
    241. Deane KD, Striebich CC, Goldstein BL, Derber LA, Parish MC, Feser ML, Hamburger EM, Brake S, Belz C, Goddard J, Norris JM, Karlson EW, Holers VM. Identification of undiagnosed inflammatory arthritis in a community health fair screen. Arthritis Rheum. 2009 Dec 15; 61(12):1642-9. PMID: 19950306.
      View in: PubMed
    242. Banda NK, Levitt B, Wood AK, Takahashi K, Stahl GL, Holers VM, Arend WP. Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro. Clin Exp Immunol. 2010 Jan; 159(1):100-8. PMID: 19843088.
      View in: PubMed
    243. Banda NK, Levitt B, Glogowska MJ, Thurman JM, Takahashi K, Stahl GL, Tomlinson S, Arend WP, Holers VM. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J Immunol. 2009 Nov 01; 183(9):5928-37. PMID: 19828624.
      View in: PubMed
    244. Gregersen PK, Amos CI, Lee AT, Lu Y, Remmers EF, Kastner DL, Seldin MF, Criswell LA, Plenge RM, Holers VM, Mikuls TR, Sokka T, Moreland LW, Bridges SL, Xie G, Begovich AB, Siminovitch KA. REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat Genet. 2009 Jul; 41(7):820-3. PMID: 19503088.
      View in: PubMed
    245. Kulik L, Fleming SD, Moratz C, Reuter JW, Novikov A, Chen K, Andrews KA, Markaryan A, Quigg RJ, Silverman GJ, Tsokos GC, Holers VM. Pathogenic natural antibodies recognizing annexin IV are required to develop intestinal ischemia-reperfusion injury. J Immunol. 2009 May 01; 182(9):5363-73. PMID: 19380783.
      View in: PubMed
    246. Thurman JM, Renner B, Kunchithapautham K, Ferreira VP, Pangburn MK, Ablonczy Z, Tomlinson S, Holers VM, Rohrer B. Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury. J Biol Chem. 2009 Jun 19; 284(25):16939-16947. PMID: 19386604.
      View in: PubMed
    247. Feser M, Derber LA, Deane KD, Lezotte DC, Weisman MH, Buckner JH, Mikuls T, O'Dell J, Gregersen PK, Holers VM, Norris JM. Plasma 25,OH vitamin D concentrations are not associated with rheumatoid arthritis (RA)-related autoantibodies in individuals at elevated risk for RA. J Rheumatol. 2009 May; 36(5):943-6. PMID: 19286844.
      View in: PubMed
    248. Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol. 2008 Dec 01; 181(11):8068-76. PMID: 19017999.
      View in: PubMed
    249. Lyubchenko T, Nielsen JP, Miller SM, Liubchenko GA, Holers VM. Role of initial protein phosphorylation events and localized release-activated calcium influx in B cell antigen receptor signaling. J Leukoc Biol. 2009 Feb; 85(2):298-309. PMID: 19028960.
      View in: PubMed
    250. Mikuls TR, Payne JB, Reinhardt RA, Thiele GM, Maziarz E, Cannella AC, Holers VM, Kuhn KA, O'Dell JR. Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis. Int Immunopharmacol. 2009 Jan; 9(1):38-42. PMID: 18848647.
      View in: PubMed
    251. Lynch AM, Gibbs RS, Murphy JR, Byers T, Neville MC, Giclas PC, Salmon JE, Van Hecke TM, Holers VM. Complement activation fragment Bb in early pregnancy and spontaneous preterm birth. Am J Obstet Gynecol. 2008 Oct; 199(4):354.e1-8. PMID: 18928972.
      View in: PubMed
    252. Young KA, Herbert AP, Barlow PN, Holers VM, Hannan JP. Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350. J Virol. 2008 Nov; 82(22):11217-27. PMID: 18786993.
      View in: PubMed
    253. Li K, Okemefuna AI, Gor J, Hannan JP, Asokan R, Holers VM, Perkins SJ. Solution structure of the complex formed between human complement C3d and full-length complement receptor type 2. J Mol Biol. 2008 Dec 05; 384(1):137-50. PMID: 18804116.
      View in: PubMed
    254. Holers VM. The spectrum of complement alternative pathway-mediated diseases. Immunol Rev. 2008 Jun; 223:300-16. PMID: 18613844.
      View in: PubMed
    255. Clark A, Weymann A, Hartman E, Turmelle Y, Carroll M, Thurman JM, Holers VM, Hourcade DE, Rudnick DA. Evidence for non-traditional activation of complement factor C3 during murine liver regeneration. Mol Immunol. 2008 Jun; 45(11):3125-32. PMID: 18452991.
      View in: PubMed
    256. Hughes LB, Morrison D, Kelley JM, Padilla MA, Vaughan LK, Westfall AO, Dwivedi H, Mikuls TR, Holers VM, Parrish LA, Alarcón GS, Conn DL, Jonas BL, Callahan LF, Smith EA, Gilkeson GS, Howard G, Moreland LW, Patterson N, Reich D, Bridges SL. The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture. Arthritis Rheum. 2008 Feb; 58(2):349-58. PMID: 18240241.
      View in: PubMed
    257. Lynch AM, Murphy JR, Byers T, Gibbs RS, Neville MC, Giclas PC, Salmon JE, Holers VM. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol. 2008 Apr; 198(4):385.e1-9. PMID: 18221926.
      View in: PubMed
    258. Zaiss AK, Cotter MJ, White LR, Clark SA, Wong NC, Holers VM, Bartlett JS, Muruve DA. Complement is an essential component of the immune response to adeno-associated virus vectors. J Virol. 2008 Mar; 82(6):2727-40. PMID: 18199646.
      View in: PubMed
    259. Mikuls TR, Hughes LB, Westfall AO, Holers VM, Parrish L, van der Heijde D, van Everdingen M, Alarcón GS, Conn DL, Jonas B, Callahan LF, Smith EA, Gilkeson G, Howard G, Moreland LW, Bridges SL. Cigarette smoking, disease severity and autoantibody expression in African Americans with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2008 Nov; 67(11):1529-34. PMID: 18198196.
      View in: PubMed
    260. Banda NK, Takahashi K, Wood AK, Holers VM, Arend WP. Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J Immunol. 2007 Sep 15; 179(6):4101-9. PMID: 17785849.
      View in: PubMed
    261. Lyubchenko T, Dal Porto JM, Holers VM, Cambier JC. Cutting edge: Complement (C3d)-linked antigens break B cell anergy. J Immunol. 2007 Sep 01; 179(5):2695-9. PMID: 17709481.
      View in: PubMed
    262. Ho J, Moir S, Kulik L, Malaspina A, Donoghue ET, Miller NJ, Wang W, Chun TW, Fauci AS, Holers VM. Role for CD21 in the establishment of an extracellular HIV reservoir in lymphoid tissues. J Immunol. 2007 Jun 01; 178(11):6968-74. PMID: 17513746.
      View in: PubMed
    263. Leinhase I, Rozanski M, Harhausen D, Thurman JM, Schmidt OI, Hossini AM, Taha ME, Rittirsch D, Ward PA, Holers VM, Ertel W, Stahel PF. Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice. J Neuroinflammation. 2007 May 02; 4:13. PMID: 17474994.
      View in: PubMed
    264. Twohig J, Kulik L, Haluszczak C, Reuter J, Rossbach A, Bull M, Holers VM, Marchbank KJ. Defective B cell ontogeny and immune response in human complement receptor 2 (CR2, CD21) transgenic mice is partially recovered in the absence of C3. Mol Immunol. 2007 Jul; 44(13):3434-44. PMID: 17379312.
      View in: PubMed
    265. Kulik L, Marchbank KJ, Lyubchenko T, Kuhn KA, Liubchenko GA, Haluszczak C, Gipson MG, Gibson MG, Boackle SA, Holers VM. Intrinsic B cell hypo-responsiveness in mice prematurely expressing human CR2/CD21 during B cell development. Eur J Immunol. 2007 Mar; 37(3):623-33. PMID: 17301948.
      View in: PubMed
    266. Looney RJ, Diamond B, Holers VM, Levesque MC, Moreland L, Nahm MH, St Clair EW. Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. Clin Immunol. 2007 Jun; 123(3):235-43. PMID: 17329169.
      View in: PubMed
    267. Schepers A, de Vries MR, van Leuven CJ, Grimbergen JM, Holers VM, Daha MR, van Bockel JH, Quax PH. Inhibition of complement component C3 reduces vein graft atherosclerosis in apolipoprotein E3-Leiden transgenic mice. Circulation. 2006 Dec 19; 114(25):2831-8. PMID: 17145993.
      View in: PubMed
    268. Thorgersen EB, Ghebremariam YT, Thurman JM, Fung M, Nielsen EW, Holers VM, Kotwal GJ, Mollnes TE. Candidate inhibitors of porcine complement. Mol Immunol. 2007 Mar; 44(8):1827-34. PMID: 17109963.
      View in: PubMed
    269. Szakonyi G, Klein MG, Hannan JP, Young KA, Ma RZ, Asokan R, Holers VM, Chen XS. Structure of the Epstein-Barr virus major envelope glycoprotein. Nat Struct Mol Biol. 2006 Nov; 13(11):996-1001. PMID: 17072314.
      View in: PubMed
    270. Mikuls TR, Holers VM, Parrish L, Kuhn KA, Conn DL, Gilkeson G, Smith EA, Kamen DL, Jonas BL, Callahan LF, Alarcón GS, Howard G, Moreland LW, Bridges SL. Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in African Americans with early rheumatoid arthritis. Arthritis Rheum. 2006 Sep; 54(9):3057-9. PMID: 16948136.
      View in: PubMed
    271. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med. 2006 Sep 04; 203(9):2165-75. PMID: 16923853.
      View in: PubMed
    272. Holers VM. Are anti-cyclic citrullinated peptide antibodies pathogenic in rheumatoid arthritis? Nat Clin Pract Rheumatol. 2006 Aug; 2(8):400-1. PMID: 16932728.
      View in: PubMed
    273. Banda NK, Thurman JM, Kraus D, Wood A, Carroll MC, Arend WP, Holers VM. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J Immunol. 2006 Aug 01; 177(3):1904-12. PMID: 16849503.
      View in: PubMed
    274. Leinhase I, Holers VM, Thurman JM, Harhausen D, Schmidt OI, Pietzcker M, Taha ME, Rittirsch D, Huber-Lang M, Smith WR, Ward PA, Stahel PF. Reduced neuronal cell death after experimental brain injury in mice lacking a functional alternative pathway of complement activation. BMC Neurosci. 2006 Jul 14; 7:55. PMID: 16842619.
      View in: PubMed
    275. Taube C, Thurman JM, Takeda K, Joetham A, Miyahara N, Carroll MC, Dakhama A, Giclas PC, Holers VM, Gelfand EW. Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation. Proc Natl Acad Sci U S A. 2006 May 23; 103(21):8084-9. PMID: 16702544.
      View in: PubMed
    276. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, Holers VM. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest. 2006 Apr; 116(4):961-73. PMID: 16585962.
      View in: PubMed
    277. Kraus DM, Elliott GS, Chute H, Horan T, Pfenninger KH, Sanford SD, Foster S, Scully S, Welcher AA, Holers VM. CSMD1 is a novel multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues. J Immunol. 2006 Apr 01; 176(7):4419-30. PMID: 16547280.
      View in: PubMed
    278. Leinhase I, Schmidt OI, Thurman JM, Hossini AM, Rozanski M, Taha ME, Scheffler A, John T, Smith WR, Holers VM, Stahel PF. Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury. Exp Neurol. 2006 Jun; 199(2):454-64. PMID: 16545803.
      View in: PubMed
    279. Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol. 2006 Feb 01; 176(3):1305-10. PMID: 16424154.
      View in: PubMed
    280. Atkinson C, Song H, Lu B, Qiao F, Burns TA, Holers VM, Tsokos GC, Tomlinson S. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest. 2005 Sep; 115(9):2444-53. PMID: 16127466.
      View in: PubMed
    281. Birrell L, Kulik L, Morgan BP, Holers VM, Marchbank KJ. B cells from mice prematurely expressing human complement receptor type 2 are unresponsive to T-dependent antigens. J Immunol. 2005 Jun 01; 174(11):6974-82. PMID: 15905540.
      View in: PubMed
    282. Thurman JM, Lucia MS, Ljubanovic D, Holers VM. Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney Int. 2005 Feb; 67(2):524-30. PMID: 15673300.
      View in: PubMed
    283. Gilbert HE, Eaton JT, Hannan JP, Holers VM, Perkins SJ. Solution structure of the complex between CR2 SCR 1-2 and C3d of human complement: an X-ray scattering and sedimentation modelling study. J Mol Biol. 2005 Feb 25; 346(3):859-73. PMID: 15713468.
      View in: PubMed
    284. Hannan JP, Young KA, Guthridge JM, Asokan R, Szakonyi G, Chen XS, Holers VM. Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d. J Mol Biol. 2005 Feb 25; 346(3):845-58. PMID: 15713467.
      View in: PubMed
    285. Carroll MC, Holers VM. Innate autoimmunity. Adv Immunol. 2005; 86:137-57. PMID: 15705421.
      View in: PubMed
    286. Thurman JM, Kraus DM, Girardi G, Hourcade D, Kang HJ, Royer PA, Mitchell LM, Giclas PC, Salmon J, Gilkeson G, Holers VM. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol. 2005 Jan; 42(1):87-97. PMID: 15488947.
      View in: PubMed
    287. Li S, Boackle SA, Holers VM, Lambris JD, Blatteis CM. Complement component c5a is integral to the febrile response of mice to lipopolysaccharide. Neuroimmunomodulation. 2005; 12(2):67-80. PMID: 15785108.
      View in: PubMed
    288. Ferucci ED, Majka DS, Parrish LA, Moroldo MB, Ryan M, Passo M, Thompson SD, Deane KD, Rewers M, Arend WP, Glass DN, Norris JM, Holers VM. Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2005 Jan; 52(1):239-46. PMID: 15641089.
      View in: PubMed
    289. Holers VM. Complement receptors and the shaping of the natural antibody repertoire. Springer Semin Immunopathol. 2005 Mar; 26(4):405-23. PMID: 15614507.
      View in: PubMed
    290. Mikuls TR, O'Dell JR, Stoner JA, Parrish LA, Arend WP, Norris JM, Holers VM. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum. 2004 Dec; 50(12):3776-82. PMID: 15593224.
      View in: PubMed
    291. Fleming SD, Egan RP, Chai C, Girardi G, Holers VM, Salmon J, Monestier M, Tsokos GC. Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice. J Immunol. 2004 Dec 01; 173(11):7055-61. PMID: 15557203.
      View in: PubMed
    292. Holers VM. Anti-C1q autoantibodies amplify pathogenic complement activation in systemic lupus erythematosus. J Clin Invest. 2004 Sep; 114(5):616-9. PMID: 15343378.
      View in: PubMed
    293. Ohta R, Kondor N, Dohi N, Tomlinson S, Imai M, Holers VM, Okada H, Okada N. Mouse complement receptor-related gene y/p65-neutralized tumor vaccine induces antitumor activity in vivo. J Immunol. 2004 Jul 01; 173(1):205-13. PMID: 15210776.
      View in: PubMed
    294. Holers VM, Thurman JM. The alternative pathway of complement in disease: opportunities for therapeutic targeting. Mol Immunol. 2004 Jun; 41(2-3):147-52. PMID: 15159060.
      View in: PubMed
    295. Boackle SA, Culhane KK, Brown JM, Haas M, Bao L, Quigg RJ, Holers VM. CR1/CR2 deficiency alters IgG3 autoantibody production and IgA glomerular deposition in the MRL/lpr model of SLE. Autoimmunity. 2004 Mar; 37(2):111-23. PMID: 15293881.
      View in: PubMed
    296. Holers VM, Boackle SA. Complement receptor 2 and autoimmunity. Curr Dir Autoimmun. 2004; 7:33-48. PMID: 14719374.
      View in: PubMed
    297. Elliott MK, Jarmi T, Ruiz P, Xu Y, Holers VM, Gilkeson GS. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int. 2004 Jan; 65(1):129-38. PMID: 14675043.
      View in: PubMed
    298. Park JW, Taube C, Joetham A, Takeda K, Kodama T, Dakhama A, McConville G, Allen CB, Sfyroera G, Shultz LD, Lambris JD, Giclas PC, Holers VM, Gelfand EW. Complement activation is critical to airway hyperresponsiveness after acute ozone exposure. Am J Respir Crit Care Med. 2004 Mar 15; 169(6):726-32. PMID: 14701711.
      View in: PubMed
    299. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, Hollmann TJ, Casali P, Caroll MC, Wetsel RA, Lambris JD, Holers VM, Salmon JE. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003 Dec; 112(11):1644-54. PMID: 14660741.
      View in: PubMed
    300. Majka DS, Holers VM. Can we accurately predict the development of rheumatoid arthritis in the preclinical phase? Arthritis Rheum. 2003 Oct; 48(10):2701-5. PMID: 14558071.
      View in: PubMed
    301. Bao L, Zhou J, Holers VM, Quigg RJ. Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation. J Am Soc Nephrol. 2003 Oct; 14(10):2516-25. PMID: 14514729.
      View in: PubMed
    302. Aslam M, Guthridge JM, Hack BK, Quigg RJ, Holers VM, Perkins SJ. The extended multidomain solution structures of the complement protein Crry and its chimeric conjugate Crry-Ig by scattering, analytical ultracentrifugation and constrained modelling: implications for function and therapy. J Mol Biol. 2003 Jun 06; 329(3):525-50. PMID: 12767833.
      View in: PubMed
    303. Holers VM. The complement system as a therapeutic target in autoimmunity. Clin Immunol. 2003 Jun; 107(3):140-51. PMID: 12804527.
      View in: PubMed
    304. Bao L, Haas M, Kraus DM, Hack BK, Rakstang JK, Holers VM, Quigg RJ. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J Am Soc Nephrol. 2003 Mar; 14(3):670-9. PMID: 12595503.
      View in: PubMed
    305. Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol. 2003 Feb 01; 170(3):1517-23. PMID: 12538716.
      View in: PubMed
    306. Boackle SA, Holers VM. Role of complement in the development of autoimmunity. Curr Dir Autoimmun. 2003; 6:154-68. PMID: 12408051.
      View in: PubMed
    307. Salmon JE, Girardi G, Holers VM. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus. 2003; 12(7):535-8. PMID: 12892394.
      View in: PubMed
    308. Perkins SJ, Gilbert HE, Aslam M, Hannan J, Holers VM, Goodship TH. Solution structures of complement components by X-ray and neutron scattering and analytical ultracentrifugation. Biochem Soc Trans. 2002 Nov; 30(Pt 6):996-1001. PMID: 12440960.
      View in: PubMed
    309. Banda NK, Kraus D, Vondracek A, Huynh LH, Bendele A, Holers VM, Arend WP. Mechanisms of effects of complement inhibition in murine collagen-induced arthritis. Arthritis Rheum. 2002 Nov; 46(11):3065-75. PMID: 12428251.
      View in: PubMed
    310. Hannan J, Young K, Szakonyi G, Overduin MJ, Perkins SJ, Chen X, Holers VM. Structure of complement receptor (CR) 2 and CR2-C3d complexes. Biochem Soc Trans. 2002 Nov; 30(Pt 6):983-9. PMID: 12440958.
      View in: PubMed
    311. Fleming SD, Shea-Donohue T, Guthridge JM, Kulik L, Waldschmidt TJ, Gipson MG, Tsokos GC, Holers VM. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J Immunol. 2002 Aug 15; 169(4):2126-33. PMID: 12165541.
      View in: PubMed
    312. Ulgiati D, Pham C, Holers VM. Functional analysis of the human complement receptor 2 (CR2/CD21) promoter: characterization of basal transcriptional mechanisms. J Immunol. 2002 Jun 15; 168(12):6279-85. PMID: 12055242.
      View in: PubMed
    313. Li S, Holers VM, Boackle SA, Blatteis CM. Modulation of mouse endotoxic fever by complement. Infect Immun. 2002 May; 70(5):2519-25. PMID: 11953391.
      View in: PubMed
    314. Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA, Takahashi K, Holers VM, Walport M, Gerard C, Ezekowitz A, Carroll MC, Brenner M, Weissleder R, Verbeek JS, Duchatelle V, Degott C, Benoist C, Mathis D. Arthritis critically dependent on innate immune system players. Immunity. 2002 Feb; 16(2):157-68. PMID: 11869678.
      View in: PubMed
    315. Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, Espinola R, Xiaowei LE, Mao D, Vialpando CG, Salmon JE. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med. 2002 Jan 21; 195(2):211-20. PMID: 11805148.
      View in: PubMed
    316. Henson SE, Smith D, Boackle SA, Holers VM, Karp DR. Generation of recombinant human C3dg tetramers for the analysis of CD21 binding and function. J Immunol Methods. 2001 Dec 01; 258(1-2):97-109. PMID: 11684127.
      View in: PubMed
    317. Rehrig S, Fleming SD, Anderson J, Guthridge JM, Rakstang J, McQueen CE, Holers VM, Tsokos GC, Shea-Donohue T. Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice. J Immunol. 2001 Nov 15; 167(10):5921-7. PMID: 11698469.
      View in: PubMed
    318. Boackle SA, Holers VM, Chen X, Szakonyi G, Karp DR, Wakeland EK, Morel L. Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity. 2001 Nov; 15(5):775-85. PMID: 11728339.
      View in: PubMed
    319. Kaya Z, Afanasyeva M, Wang Y, Dohmen KM, Schlichting J, Tretter T, Fairweather D, Holers VM, Rose NR. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat Immunol. 2001 Aug; 2(8):739-45. PMID: 11477411.
      View in: PubMed
    320. Park P, Haas M, Cunningham PN, Alexander JJ, Bao L, Guthridge JM, Kraus DM, Holers VM, Quigg RJ. Inhibiting the complement system does not reduce injury in renal ischemia reperfusion. J Am Soc Nephrol. 2001 Jul; 12(7):1383-1390. PMID: 11423567.
      View in: PubMed
    321. Guthridge JM, Rakstang JK, Young KA, Hinshelwood J, Aslam M, Robertson A, Gipson MG, Sarrias MR, Moore WT, Meagher M, Karp D, Lambris JD, Perkins SJ, Holers VM. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg. Biochemistry. 2001 May 22; 40(20):5931-41. PMID: 11352728.
      View in: PubMed
    322. Sekine H, Reilly CM, Molano ID, Garnier G, Circolo A, Ruiz P, Holers VM, Boackle SA, Gilkeson GS. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol. 2001 May 15; 166(10):6444-51. PMID: 11342671.
      View in: PubMed
    323. Makar KW, Ulgiati D, Hagman J, Holers VM. A site in the complement receptor 2 (CR2/CD21) silencer is necessary for lineage specific transcriptional regulation. Int Immunol. 2001 May; 13(5):657-64. PMID: 11312253.
      View in: PubMed
    324. Schiller B, Cunningham PN, Alexander JJ, Bao L, Holers VM, Quigg RJ. Expression of a soluble complement inhibitor protects transgenic mice from antibody-induced acute renal failure. J Am Soc Nephrol. 2001 Jan; 12(1):71-79. PMID: 11134252.
      View in: PubMed
    325. Holers VM. Phenotypes of complement knockouts. Immunopharmacology. 2000 Aug; 49(1-2):125-31. PMID: 10904112.
      View in: PubMed
    326. Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, Holers VM, Boackle SA, Colten HR, Gilkeson GS. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol. 2000 Jan 15; 164(2):786-94. PMID: 10623824.
      View in: PubMed
    327. Karp DR, Carlisle ML, Mobley AB, Nichols TC, Oppenheimer-Marks N, Brezinschek RI, Holers VM. Gamma-glutamyl transpeptidase is up-regulated on memory T lymphocytes. Int Immunol. 1999 Nov; 11(11):1791-800. PMID: 10545483.
      View in: PubMed
    328. Holers VM. Complement deficiency states, disease susceptibility, and infection risk in systemic lupus erythematosus. Arthritis Rheum. 1999 Oct; 42(10):2023-5. PMID: 10524672.
      View in: PubMed
    329. Henson SE, Nichols TC, Holers VM, Karp DR. The ectoenzyme gamma-glutamyl transpeptidase regulates antiproliferative effects of S-nitrosoglutathione on human T and B lymphocytes. J Immunol. 1999 Aug 15; 163(4):1845-52. PMID: 10438918.
      View in: PubMed
    330. Davoust N, Nataf S, Holers VM, Barnum SR. Expression of the murine complement regulatory protein crry by glial cells and neurons. Glia. 1999 Aug; 27(2):162-70. PMID: 10417815.
      View in: PubMed
    331. Nardin A, Schlimgen R, Holers VM, Taylor RP. A prototype pathogen bound ex vivo to human erythrocyte complement receptor 1 via bispecific monoclonal antibody complexes is cleared to the liver in a mouse model. Eur J Immunol. 1999 05; 29(5):1581-6. PMID: 10359112.
      View in: PubMed
    332. Nichols TC, Guthridge JM, Karp DR, Molina H, Fletcher DR, Holers VM. Gamma-glutamyl transpeptidase, an ecto-enzyme regulator of intracellular redox potential, is a component of TM4 signal transduction complexes. Eur J Immunol. 1998 12; 28(12):4123-9. PMID: 9862348.
      View in: PubMed
    333. Quigg RJ, He C, Lim A, Berthiaume D, Alexander JJ, Kraus D, Holers VM. Transgenic mice overexpressing the complement inhibitor crry as a soluble protein are protected from antibody-induced glomerular injury. J Exp Med. 1998 Oct 05; 188(7):1321-31. PMID: 9763611.
      View in: PubMed
    334. Kozono Y, Abe R, Kozono H, Kelly RG, Azuma T, Holers VM. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells. J Immunol. 1998 Feb 15; 160(4):1565-72. PMID: 9469411.
      View in: PubMed
    335. Makar KW, Pham CT, Dehoff MH, O'Connor SM, Jacobi SM, Holers VM. An intronic silencer regulates B lymphocyte cell- and stage-specific expression of the human complement receptor type 2 (CR2, CD21) gene. J Immunol. 1998 Feb 01; 160(3):1268-78. PMID: 9570543.
      View in: PubMed
    336. Quigg RJ, Alexander JJ, Lo CF, Lim A, He C, Holers VM. Characterization of C3-binding proteins on mouse neutrophils and platelets. J Immunol. 1997 Sep 01; 159(5):2438-44. PMID: 9278336.
      View in: PubMed
    337. Takahashi K, Kozono Y, Waldschmidt TJ, Berthiaume D, Quigg RJ, Baron A, Holers VM. Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J Immunol. 1997 Aug 01; 159(3):1557-69. PMID: 9233655.
      View in: PubMed
    338. Kearns-Jonker M, Monell-Torrens E, Abbasi F, Holers VM, Notkins AL, Sigounas G. EBV binds to lymphocytes of transgenic mice that express the human CR2 gene. Virus Res. 1997 Jul; 50(1):85-94. PMID: 9255938.
      View in: PubMed
    339. Kawamoto Y, Kojima K, Hitsumoto Y, Okada H, Holers VM, Miyama A. The serum resistance of malaria-infected erythrocytes. Immunology. 1997 May; 91(1):7-12. PMID: 9203959.
      View in: PubMed
    340. Boackle SA, Holers VM, Karp DR. CD21 augments antigen presentation in immune individuals. Eur J Immunol. 1997 Jan; 27(1):122-9. PMID: 9022008.
      View in: PubMed
    341. Sawant-Mane S, Piddlesden SJ, Morgan BP, Holers VM, Koski CL. CD59 homologue regulates complement-dependent cytolysis of rat Schwann cells. J Neuroimmunol. 1996 Sep; 69(1-2):63-71. PMID: 8823377.
      View in: PubMed
    342. Kozono Y, Kotzin BL, Holers VM. Resting B cells from New Zealand Black mice demonstrate a defect in apoptosis induction following surface IgM ligation. J Immunol. 1996 Jun 01; 156(11):4498-503. PMID: 8666826.
      View in: PubMed
    343. Rogers CA, Gasque P, Piddlesden SJ, Okada N, Holers VM, Morgan BP. Expression and function of membrane regulators of complement on rat astrocytes in culture. Immunology. 1996 May; 88(1):153-61. PMID: 8707343.
      View in: PubMed
    344. Molina H, Holers VM, Li B, Fung Y, Mariathasan S, Goellner J, Strauss-Schoenberger J, Karr RW, Chaplin DD. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc Natl Acad Sci U S A. 1996 Apr 16; 93(8):3357-61. PMID: 8622941.
      View in: PubMed
    345. Quigg RJ, Holers VM. Characterization of rat complement receptors and regulatory proteins. CR2 and Crry are conserved, and the C3b receptor of neutrophils and platelets is distinct from CR1. J Immunol. 1995 Aug 01; 155(3):1481-8. PMID: 7636211.
      View in: PubMed
    346. Quigg RJ, Morgan BP, Holers VM, Adler S, Sneed AE, Lo CF. Complement regulation in the rat glomerulus: Crry and CD59 regulate complement in glomerular mesangial and endothelial cells. Kidney Int. 1995 Aug; 48(2):412-21. PMID: 7564108.
      View in: PubMed
    347. Dunster LM, Schneider-Schaulies J, Dehoff MH, Holers VM, Schwartz-Albiez R, ter Meulen V. Moesin, and not the murine functional homologue (Crry/p65) of human membrane cofactor protein (CD46), is involved in the entry of measles virus (strain Edmonston) into susceptible murine cell lines. J Gen Virol. 1995 Aug; 76 ( Pt 8):2085-9. PMID: 7636492.
      View in: PubMed
    348. Shima M, Teitelbaum SL, Holers VM, Ruzicka C, Osmack P, Ross FP. Macrophage-colony-stimulating factor regulates expression of the integrins alpha 4 beta 1 and alpha 5 beta 1 by murine bone marrow macrophages. Proc Natl Acad Sci U S A. 1995 May 23; 92(11):5179-83. PMID: 7539144.
      View in: PubMed
    349. Molina H, Perkins SJ, Guthridge J, Gorka J, Kinoshita T, Holers VM. Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3. An initial model of ligand interaction with two linked short consensus repeat modules. J Immunol. 1995 May 15; 154(10):5426-35. PMID: 7730644.
      View in: PubMed
    350. Quigg RJ, Holers VM, Morgan BP, Sneed AE. Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. J Immunol. 1995 Apr 01; 154(7):3437-43. PMID: 7534798.
      View in: PubMed
    351. Kim YU, Kinoshita T, Molina H, Hourcade D, Seya T, Wagner LM, Holers VM. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med. 1995 Jan 01; 181(1):151-9. PMID: 7528766.
      View in: PubMed
    352. Graham IL, Anderson DC, Holers VM, Brown EJ. Complement receptor 3 (CR3, Mac-1, integrin alpha M beta 2, CD11b/CD18) is required for tyrosine phosphorylation of paxillin in adherent and nonadherent neutrophils. J Cell Biol. 1994 Nov; 127(4):1139-47. PMID: 7525604.
      View in: PubMed
    353. Molina H, Kinoshita T, Webster CB, Holers VM. Analysis of C3b/C3d binding sites and factor I cofactor regions within mouse complement receptors 1 and 2. J Immunol. 1994 Jul 15; 153(2):789-95. PMID: 8021513.
      View in: PubMed
    354. Aubry JP, Pochon S, Gauchat JF, Nueda-Marin A, Holers VM, Graber P, Siegfried C, Bonnefoy JY. CD23 interacts with a new functional extracytoplasmic domain involving N-linked oligosaccharides on CD21. J Immunol. 1994 Jun 15; 152(12):5806-13. PMID: 7515913.
      View in: PubMed
    355. Li B, Sallee C, Dehoff M, Foley S, Molina H, Holers VM. Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J Immunol. 1993 Oct 15; 151(8):4295-305. PMID: 7691944.
      View in: PubMed
    356. Foley S, Li B, Dehoff M, Molina H, Holers VM. Mouse Crry/p65 is a regulator of the alternative pathway of complement activation. Eur J Immunol. 1993 Jun; 23(6):1381-4. PMID: 8500531.
      View in: PubMed
    357. Levy E, Ambrus J, Kahl L, Molina H, Tung K, Holers VM. T lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1992 Nov; 90(2):235-44. PMID: 1424280.
      View in: PubMed
    358. Emlen W, Holers VM, Arend WP, Kotzin B. Regulation of nuclear antigen expression on the cell surface of human monocytes. J Immunol. 1992 May 15; 148(10):3042-8. PMID: 1578130.
      View in: PubMed
    359. Hourcade D, Garcia AD, Post TW, Taillon-Miller P, Holers VM, Wagner LM, Bora NS, Atkinson JP. Analysis of the human regulators of complement activation (RCA) gene cluster with yeast artificial chromosomes (YACs). Genomics. 1992 Feb; 12(2):289-300. PMID: 1740338.
      View in: PubMed
    360. Krych M, Atkinson JP, Holers VM. Complement receptors. Curr Opin Immunol. 1992 Feb; 4(1):8-13. PMID: 1596373.
      View in: PubMed
    361. Molina H, Brenner C, Jacobi S, Gorka J, Carel JC, Kinoshita T, Holers VM. Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction. J Biol Chem. 1991 Jul 05; 266(19):12173-9. PMID: 1712014.
      View in: PubMed
    362. Carel JC, Holers VM, Chick WL, Littman D, Lacy PE. Expression of functional human Epstein-Barr virus/C3d receptor ([CR2] CD21) on insulinoma cell line. Induction of tumor rejection but not diabetes in syngeneic rats. Diabetes. 1991 Jul; 40(7):809-14. PMID: 1647992.
      View in: PubMed
    363. Ballard LL, Brown EJ, Holers VM. Expression of the fibronectin receptor VLA-5 is regulated during human B cell differentiation and activation. Clin Exp Immunol. 1991 May; 84(2):336-46. PMID: 1709071.
      View in: PubMed
    364. Rayhel EJ, Dehoff MH, Holers VM. Characterization of the human complement receptor 2 (CR2, CD21) promoter reveals sequences shared with regulatory regions of other developmentally restricted B cell proteins. J Immunol. 1991 Mar 15; 146(6):2021-6. PMID: 1706386.
      View in: PubMed
    365. Carel JC, Myones BL, Frazier B, Holers VM. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. J Biol Chem. 1990 Jul 25; 265(21):12293-9. PMID: 1695627.
      View in: PubMed
    366. Secrist H, Holers VM, Levine A, Egan M, Nahm MH, Butch AW, Peters M. Induction of IL-4 and IL-6 synthesis in vitro: variation in signaling requirements and kinetics are dependent on the anatomic source of the responding mononuclear cells. Reg Immunol. 1990-1991; 3(6):341-8. PMID: 2132759.
      View in: PubMed
    367. Hourcade D, Post TW, Holers VM, Lublin DM, Atkinson JP. Polymorphisms of the regulators of complement activation gene cluster. Complement Inflamm. 1990; 7(4-6):302-14. PMID: 2088670.
      View in: PubMed
    368. Carel JC, Frazier B, Ley TJ, Holers VM. Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells. J Immunol. 1989 Aug 01; 143(3):923-30. PMID: 2473114.
      View in: PubMed
    369. Holers VM, Ruff TG, Parks DL, McDonald JA, Ballard LL, Brown EJ. Molecular cloning of a murine fibronectin receptor and its expression during inflammation. Expression of VLA-5 is increased in activated peritoneal macrophages in a manner discordant from major histocompatibility complex class II. J Exp Med. 1989 May 01; 169(5):1589-605. PMID: 2523953.
      View in: PubMed
    370. Fujisaku A, Harley JB, Frank MB, Gruner BA, Frazier B, Holers VM. Genomic organization and polymorphisms of the human C3d/Epstein-Barr virus receptor. J Biol Chem. 1989 Feb 05; 264(4):2118-25. PMID: 2563370.
      View in: PubMed
    371. Bora NS, Lublin DM, Kumar BV, Hockett RD, Holers VM, Atkinson JP. Structural gene for human membrane cofactor protein (MCP) of complement maps to within 100 kb of the 3' end of the C3b/C4b receptor gene. J Exp Med. 1989 Feb 01; 169(2):597-602. PMID: 2521358.
      View in: PubMed
    372. Holers VM. Complement receptors. Year Immunol. 1989; 4:231-40. PMID: 2538973.
      View in: PubMed
    373. Hourcade D, Holers VM, Atkinson JP. The regulators of complement activation (RCA) gene cluster. Adv Immunol. 1989; 45:381-416. PMID: 2665442.
      View in: PubMed
    374. Hourcade D, Miesner DR, Atkinson JP, Holers VM. Identification of an alternative polyadenylation site in the human C3b/C4b receptor (complement receptor type 1) transcriptional unit and prediction of a secreted form of complement receptor type 1. J Exp Med. 1988 Oct 01; 168(4):1255-70. PMID: 2971757.
      View in: PubMed
    375. McNearney TA, Odell C, Holers VM, Spear PG, Atkinson JP. Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity. J Exp Med. 1987 Nov 01; 166(5):1525-35. PMID: 2824652.
      View in: PubMed
    376. Lublin DM, Lemons RS, Le Beau MM, Holers VM, Tykocinski ML, Medof ME, Atkinson JP. The gene encoding decay-accelerating factor (DAF) is located in the complement-regulatory locus on the long arm of chromosome 1. J Exp Med. 1987 Jun 01; 165(6):1731-6. PMID: 2438369.
      View in: PubMed
    377. Van Dyne S, Holers VM, Lublin DM, Atkinson JP. The polymorphism of the C3b/C4b receptor in the normal population and in patients with systemic lupus erythematosus. Clin Exp Immunol. 1987 Jun; 68(3):570-9. PMID: 2958190.
      View in: PubMed
    378. Holers VM, Chaplin DD, Leykam JF, Gruner BA, Kumar V, Atkinson JP. Human complement C3b/C4b receptor (CR1) mRNA polymorphism that correlates with the CR1 allelic molecular weight polymorphism. Proc Natl Acad Sci U S A. 1987 Apr; 84(8):2459-63. PMID: 3031685.
      View in: PubMed
    379. Medof ME, Lublin DM, Holers VM, Ayers DJ, Getty RR, Leykam JF, Atkinson JP, Tykocinski ML. Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci U S A. 1987 Apr; 84(7):2007-11. PMID: 2436222.
      View in: PubMed
    380. Yu GH, Holers VM, Seya T, Ballard L, Atkinson JP. Identification of a third component of complement-binding glycoprotein of human platelets. J Clin Invest. 1986 Aug; 78(2):494-501. PMID: 2942562.
      View in: PubMed
    381. Nickells MW, Seya T, Holers VM, Atkinson JP. Analysis of C3b/C4b receptor (CR1) polymorphic variants by tryptic peptide mapping. Mol Immunol. 1986 Jun; 23(6):661-8. PMID: 2943987.
      View in: PubMed
    382. Holers VM, Seya T, Brown E, O'Shea JJ, Atkinson JP. Structural and functional studies on the human C3b/C4b receptor (CR1) purified by affinity chromatography using a monoclonal antibody. Complement. 1986; 3(2):63-78. PMID: 2945695.
      View in: PubMed
    383. Holers VM, Kotzin BL. Human peripheral blood monocytes display surface antigens recognized by monoclonal antinuclear antibodies. J Clin Invest. 1985 Sep; 76(3):991-8. PMID: 3876357.
      View in: PubMed
    384. Holers VM, Cole JL, Lublin DM, Seya T, Atkinson JP. Human C3b- and C4b-regulatory proteins: a new multi-gene family. Immunol Today. 1985 Jun; 6(6):188-92. PMID: 25289982.
      View in: PubMed
    385. Rosenberg NL, Lacy JR, Kennaugh RC, Holers VM, Neville HE, Kotzin BL. Treatment of refractory chronic demyelinating polyneuropathy with lymphoid irradiation. Muscle Nerve. 1985 Mar-Apr; 8(3):223-32. PMID: 3877236.
      View in: PubMed
    Holers's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2022 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)